Meta-analysis: Serological markers and the risk of acute and chronic pouchitis

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 9, 2013, Pages 867-875

  Singh, S ^a   Sharma, P K ^a   Loftus Jr , E V ^a   Pardi, D S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FUNGUS ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANASTOMOSIS; ANTIBODY TITER; ARTICLE; CHRONIC DISEASE; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; ILEITIS; ILEUM POUCH; INFECTION RISK; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SEROLOGY; ULCERATIVE COLITIS;

ACUTE DISEASE; ANAL CANAL; ANASTOMOSIS, SURGICAL; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CHRONIC DISEASE; COLITIS, ULCERATIVE; COLONIC POUCHES; HUMANS; POUCHITIS; PROCTOCOLECTOMY, RESTORATIVE; RISK FACTORS; SACCHAROMYCES CEREVISIAE;

EID: 84875842348     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12274     Document Type: Article

References (55)

1. Leijonmarck CE, Persson PG, Hellers G,. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990; 31: 329-33.
2. Dhillon S, Loftus EV, Tremaine WJ, et al,. The natural history of surgery for ulcerative colitis in a population-based cohort from Olmsted County, Minnesota. Am J Gastroenterol 2005; 100: S303.
3. Kaplan GG, Seow CH, Ghosh S, et al,. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012; 107: 1879-87.
4. Penna C, Dozois R, Tremaine W, et al,. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-9.
5. Fazio VW, Ziv Y, Church JM, et al,. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222: 120-7.
6. Ferrante M, Declerck S, De Hertogh G, et al,. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis 2008; 14: 20-8.
7. Simchuk EJ, Thirlby RC,. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000; 24: 851-6.
8. Kuisma JHH, Jarvinen H, Luukkonen P, Kahri A, Farkkila M,. Long-term outcome of patients after IPAA for ulcerative colitis. Gastroenterology 1998; 114: A23.
9. Shen B, Remzi FH, Lavery IC, Lashner BA, Fazio VW,. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol 2008; 6: 145-58.
10. Shen B,. Acute and chronic pouchitis-pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2012; 9: 323-33.
11. Mowschenson PM, Critchlow JF, Peppercorn MA,. Ileoanal pouch operation: long-term outcome with or without diverting ileostomy. Arch Surg 2000; 135: 463-5.
12. Hurst RD, Chung TP, Rubin M, Michelassi F,. The implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm Bowel Dis 1998; 4: 280-4.
13. Prudhomme M, Dehni N, Dozois RR, Tiret E, Parc R,. Causes and outcomes of pouch excision after restorative proctocolectomy. Br J Surg 2006; 93: 82-6.
14. Hashavia E, Dotan I, Rabau M, Klausner JM, Halpern Z, Tulchinsky H,. Risk factors for chronic pouchitis after ileal pouch-anal anastomosis: a prospective cohort study. Colorectal Dis 2012; 14: 1365-71.
15. Prideaux L, De Cruz P, Ng SC, Kamm MA,. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012; 18: 1340-55.
16. Fleshner PR, Vasiliauskas EA, Kam LY, et al,. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001; 49: 671-7.
17. Aisenberg J, Legnani PE, Nilubol N, et al,. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol 2004; 99: 432-41.
18. Esteve M, Mallolas J, Klaassen J, et al,. Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis. Gut 1996; 38: 894-8.
19. Coukos JA, Howard LA, Weinberg JM, Becker JM, Stucchi AF, Farraye FA,. ASCA IgG and CBir antibodies are associated with the development of Crohn's disease and fistulae following ileal pouch-anal anastomosis. Dig Dis Sci 2012; 57: 1544-53.
20. Tyler AD, Milgrom R, Xu W, et al,. Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2012; 10: 507-12.
21. Navaneethan U, Shen B,. Laboratory tests for patients with ileal pouch-anal anastomosis: clinical utility in predicting, diagnosing, and monitoring pouch disorders. Am J Gastroenterol 2009; 104: 2606-15.
22. Stroup DF, Berlin JA, Morton SC, et al,. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
23. Stang A,. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5.
24. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
26. Kanwal F, White D,. "Systematic reviews and Meta-analyses" in clinical gastroenterology and hepatology. Clin Gastroenterol Hepatol 2012; 10: 1184-6.
27. Thompson SG, Pocock SJ,. Can meta-analyses be trusted? Lancet 1991; 338: 1127-30.
28. Guyatt GH, Oxman AD, Kunz R, et al,. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011; 64: 1294-302.
29. Sterne JA, Sutton AJ, Ioannidis JP, et al,. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.
30. Borenstein MHL, Higgins J, Rothstein H,. Comprehensive Meta-Analysis. 2nd ed. Englewood, NJ: Biostat, 2005. Available at: http://www.meta-analysis.com/ pages/about-us.html.
31. Brett PM, Yasuda N, Yiannakou JY, et al,. Genetic and immunological markers in pouchitis. Eur J Gastroenterol Hepat 1996; 8: 951-5.
32. Dendrinos KG, Becker JM, Stucchi AF, Saubermann LJ, LaMorte W, Farraye FA,. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. JOGS 2006; 10: 1060-4.
33. Fleshner P, Ippoliti A, Dubinsky M, et al,. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after heal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008; 6: 561-8.
34. Reumaux D, Colombel JF, Masy E, et al,. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm Bowel Dis 2000; 6: 270-4.
35. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR,. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995; 90: 740-7.
36. Tyler AD, Milgrom R, Stempak JM, et al,. The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut 2012; doi: 10.1136/gutjnl-2011-301957 [Epub ahead of print].
37. Vecchi M, Gionchetti P, Bianchi MB, et al,. p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 1994; 344: 886-7.
38. Yang P, Oresland T, Jarnerot G, Hulten L, Danielsson D,. Perinuclear antineutrophil cytoplasmic antibody in pouchitis after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Scand J Gastroenterol 1996; 31: 594-8.
39. Aisenberg J, Wagreich J, Shim J, et al,. Perinuclear antineutrophil cytoplasmic antibody and refractory pouchitis-a case control study. Digest Dis Sci 1995; 40: 1866-72.
40. Esteve M, Mallolas J, Klaassen J, et al,. Factors related to the presence of IgA class antineutrophil cytoplasmic antibodies in ulcerative colitis. Am J Gastroenterol 1998; 93: 615-8.
41. White E, Melmed GY, Vasiliauskas EA, et al,. A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis. Dis Colon Rectum 2010; 53: 987-94.
42. Yasuda N, Thomas P, Ellis H, Herbst F, Nicholls J, Ciclitira P,. Perinuclear anti-neutrophil cytoplasmic antibodies in ulcerative colitis after restorative proctocolectomy do not correlate with the presence of pouchitis. Scand J Gastroenterol 1998; 33: 509-13.
43. Kuisma J, Jarvinen H, Kahri A, Farkkila M,. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol 2004; 39: 544-8.
44. Patel RT, Stokes R, Birch D, Ibbotson J, Keighley MR,. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Brit J Surg 1994; 81: 724-6.
45. Tulchinsky H, Hawley PR, Nicholls J,. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003; 238: 229-34.
46. Achkar JP, Al-Haddad M, Lashner B, et al,. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol 2005; 3: 60-6.
47. Fleshner P, Ippoliti A, Dubinsky M, et al,. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2007; 5: 952-8.
48. Shen B, Remzi FH, Nutter B, et al,. Association between immune-associated disorders and adverse outcomes of ileal pouch-anal anastomosis. Am J Gastroenterol 2009; 104: 655-64.
49. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR,. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71: 431-6.
50. Solberg IC, Lygren I, Cvancarova M, et al,. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 406-14.
51. Dubinsky MC, Mei L, Friedman M, et al,. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1357-66.
52. Hoie O, Aamodt G, Vermeire S, et al,. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. J Crohns Colitis 2008; 2: 114-22.
53. Vecchi M, Bianchi MB, Sinico RA, et al,. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion 1994; 55: 34-9.
54. Aitola P, Miettinen A, Mattila A, Matikainen M, Soppi E,. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. J Clin Pathol 1995; 48: 645-7.
55. Shen B, Yu C, Lian L, et al,. Prediction of late-onset pouch failure in patients with restorative proctocolectomy with a nomogram. J Crohns Colitis 2012; 6: 198-206.